Print
Email
Print Edition StoriesMonday, March 8, 2010
Acetylon licenses drug tech from Harvard, Dana-Farber
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Acetylon Pharmaceuticals Inc. reports it has licensed a drug discovery platform and a group of enzyme inhibitors from Harvard University and the Dana-Farber Cancer Institute.
Under the deal, Boston-based Acetylon will license a “platform technology and chemical methodology” to screen for compounds that inhibit histone deacetylase (HDAC). The company will also license small molecules that selectively inhibit HDAC.
Financial terms of the transaction were not disclosed.
HDAC is a target for drugs that could be used to treat inflammatory disease, neurologic disease and in cancer, according to Acetylon. The company is developing drug candidates based on Class 2 selective HDAC inhibitors.
The platform and methodology were developed by Acetylon co-founders James Bradner of Dana-Farber and Ralph Mazitschek of Massachusetts General Hospital, as well as colleagues at the Broad Institute of Harvard and MIT.
In January, Acetylon pulled in $2 million in funding, bringing the total investment in the company to $9.25 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
